[HTML][HTML] RELAY, ramucirumab plus erlotinib (RAM+ ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung Cancer, 2023 - Elsevier
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase 3 trial in patients with untreated …
RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung …, 2023 - europepmc.org
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
[引用][C] RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and …
M Nishio, L Paz-Ares, M Reck… - Clinical Lung …, 2023 - produccioncientifica.ucm.es
RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung …, 2023 - repository.icr.ac.uk
BACKGROUND: Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior
progression-free survival (PFS) in RELAY, a randomised Phase III trial in patients with …
progression-free survival (PFS) in RELAY, a randomised Phase III trial in patients with …
RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical …
M Nishio, L Paz-Ares, M Reck… - Clinical lung …, 2023 - pubmed.ncbi.nlm.nih.gov
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - CLINICAL LUNG …, 2023 - iris.unito.it
Background: Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
[HTML][HTML] RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and …
M Nishio, L Paz-Ares, M Reck… - Clinical Lung …, 2023 - clinical-lung-cancer.com
Background Ramucirumab plus erlotinib (RAM+ ERL) demonstrated superior progression-
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
free survival (PFS) in RELAY, a randomised Phase III trial in patients with untreated …
[PDF][PDF] RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung …, 2023 - iris.unito.it
Mutant TP53 is a negative prognostic factor in patients with EGFR+NSCLC. This exploratory
analysis investigated the association between TP53 status and clinical outcome in RELAY …
analysis investigated the association between TP53 status and clinical outcome in RELAY …
[PDF][PDF] RELAY, Ramucirumab Plus Erlotinib (RAM+ ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and …
M Nishio, L Paz-Ares, M Reck, K Nakagawa… - Clinical Lung …, 2023 - repository.icr.ac.uk
Mutant TP53 is a negative prognostic factor in patients with EGFR+NSCLC. This exploratory
analysis investigated the association between TP53 status and clinical outcome in RELAY …
analysis investigated the association between TP53 status and clinical outcome in RELAY …